Wells Fargo initiated coverage of Ideaya Biosciences (IDYA) with an Overweight rating and $44 price target The firm does not think the Street is pricing in enough value for darovasertib’s potential in uveal melanoma. The company’s updates expected in 2025 should “de-risk” the drug in both first-line metastatic uveal melanoma and the neo adjuvant setting, the analyst tells investors in a research note. Further, updates from Ideaya’s early pipeline should offer upside in the next 12-18 months, contends Wells.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- IDEAYA Biosciences Holds Annual Stockholders Meeting
- Optimistic Buy Rating for IDEAYA Biosciences: Expanding Market Potential and Promising Clinical Data
- Ideaya Biosciences announces inducement grants under Nasdaq listing rule
- IDEAYA Biosciences: Buy Rating on Anticipated Success of Darovasertib Trial and Stock Appreciation Potential
- IDEAYA Biosciences: Promising Advancements and Strategic Initiatives Drive Buy Rating